CN Patent

CN102821759A — 用于治疗具有慢性活性b细胞受体信号传导的b细胞淋巴瘤的pkc抑制剂

Assigned to Novartis Vaccines and Diagnostics Inc · Expires 2012-12-12 · 13y expired

What this patent protects

本发明证实透过CD79A/B进行的慢性活性BCR信号传导强烈依赖下游PKCb激酶信号传导。因此，本发明提供一种抑制具有慢性活性B细胞受体信号传导的B细胞淋巴瘤生长或抑制具有导致慢性活性BCR信号传导的分子损伤的癌生长的方法，其是对需要此治疗的患者给予治疗有效量的PKC抑制剂，或使用PKC抑制剂，以抑制具有慢性活性B细胞受体信号传导的B细胞淋巴瘤生长或抑制具有导致慢性活性BCR信号传导的分子损伤的癌生长。

USPTO Abstract

本发明证实透过CD79A/B进行的慢性活性BCR信号传导强烈依赖下游PKCb激酶信号传导。因此，本发明提供一种抑制具有慢性活性B细胞受体信号传导的B细胞淋巴瘤生长或抑制具有导致慢性活性BCR信号传导的分子损伤的癌生长的方法，其是对需要此治疗的患者给予治疗有效量的PKC抑制剂，或使用PKC抑制剂，以抑制具有慢性活性B细胞受体信号传导的B细胞淋巴瘤生长或抑制具有导致慢性活性BCR信号传导的分子损伤的癌生长。

Drugs covered by this patent

Patent Metadata

Patent number
CN102821759A
Jurisdiction
CN
Classification
—
Expires
2012-12-12
Drug substance claim
No
Drug product claim
No
Assignee
Novartis Vaccines and Diagnostics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.